ESSA New Data on EPI-7386 at ESMO 2019

ESSA Pharma Inc. (Nasdaq: EPIX) (TSXV: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ESSA’s lead Investigational New Drug (“IND”) candidate at the 2019 American Urological Association (“AUA”) Annual Meeting.

In an oral poster presentation titled, “EPI-7386 is a novel N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer”, a deeper preclinical characterization of EPI-7386 was presented. The poster shows that, in preclinical studies, EPI-7386 demonstrates:

• Activity in multiple in vitro full length androgen receptor (AR) and AR-V7 splice variant driven cellular models.
• Robust antitumor activity as a single agent and in combination with enzalutamide in the VCaP xenograft prostate cancer model.
• Antitumor activity in enzalutamide-resistant prostate cancer xenograft models, 22Rv1 and LNCaP95, with no antitumor activity, as expected, in a non-functional androgen receptor PC-3 prostate cancer xenograft model.
• Wide therapeutic index as demonstrated by a broad dose response in the VCaP model.
• High plasma exposures in animal studies using a new suspension formulation.

https://www.marketscreener.com/news/ESSA-Pharma-Presents-New-Data-on-EPI-7386-at-the-European-Society-of-Medical-Oncology-ESMO-2019-Co–29274084/